Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Genetic Testing…
Browsing: Colorectal
Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Thoughts On…
Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Managing 2nd…
Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, BEACON Study…
Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses The Use Of Regorafenib In The Management Of Advanced…
Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses Patient Selection & Treatment Algorithms In 2nd And 3rd…
Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses The Role Of Circulating Tumor DNA (ctDNA). At The…
Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses CCTG CO.26 Trial In Advanced Refractory CRC Presented At…
Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses Next Generation Sequencing And mCRC. At The 2019 Gastrointestinal…
Alan Venook, MD, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF,…
Alan Venook, MD, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF,…
Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine,…
Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine,…
Fa-Chyi Lee, MD, UC Irvine Health, talks about Adjuvant Chemotherapy for Rectal Cancer | Possibly Use Single-Agent Capecitabine at MOASC…
Fa-Chyi Lee, MD, UC Irvine Health, talks about a possible Better Approach in the Next 1-2 Years | For RAS…
Fa-Chyi Lee, MD, UC Irvine Health, talks about the Major Impact from HIPEC is Insurance Reimbursement | Insurance Companies Feel…
Fa-Chyi Lee, MD, UC Irvine Health, talks about the Negative Results from HIPEC Study | Surgery May Still Have Role…
Yung Lyou, MD, UC Irvine Health, talks about 3 Clinical Trials in Non-Colorectal GI Cancers | REACH-2, KEYNOTE-061, PRODIGE 24…
Fa-Chyi Lee, MD, UC Irvine Health, talks about the HIPEC Study Requires Further Evaluation | Closed United States Intergroup Study…
Howard Hochster, MD, shares his perspective on the outcomes of the PRODIGY7 study in metastatic colorectal cancer patients using heated…
John Leighton, MD, shares his thoughts on the headline Immunotherapy Now Standard for Some Patients With Colorectal Cancer
Atrayee Basu Mallick, MD, shares the advances in the treatment of colorectal cancer
Howard Hochster, MD, weighs in on the VALENTINO study regarding the effectiveness of maintenance 5FU/LV following FOLFOX + panitumumab induction…
Atrayee Basu Mallick, MD, talks about how tumor-sidedness impacts her colorectal cancer (CRC) treatment algorithms at Annual Meeting 2018.
Howard Hochster, MD, explains the outcomes of the ECOG-7208 study in 2nd line metastatic colorectal cancer (mCRC) patients at Annual…
Atrayee Basu Mallick, MD, shares how nivolumab is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms at Annual Meeting…
John Leighton, MD, explains whether tumor sidedness impacts colorectal cancer treatment algorithms at Annual Meeting 2018.
Atrayee Basu Mallick, MD, shares her thoughts on the outcomes of the Checkmate 142 study looking ipilimumab and nivolumab in…
Atrayee Basu Mallick, MD, talks about the patient type and setting where vemurafenib has been added to the NCCN guidelines…
Atrayee Basu Mallick, MD, shares her thoughts on immunotherapy in colorectal cancer at Annual Meeting 2018.
Al Benson III, MD, FACP, explains how tumor-sidedness impacts colorectal cancer treatment algorithms.
Al Benson III, MD, FACP, explains the role of I-O and immunotherapy when treating colorectal cancer.
Dr. Benson, Professor of Medicine, Northwestern University, shares which molecular markers are most important when treating colorectal cancer patients.
Vicky Coyle, MD, of Queen’s University Belfast, Belfast, UK, spoke to us at the UK Oncology Forum (OF) 2018, held…
Aspirin has been suggested as a preventative measure for several cancer types, in particular colorectal cancer, as Vicky Coyle, MD,…
Kai-Keen Shiu, MRCP, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, speaks to us about future directions…
Scott Kopetz, M.D., Ph.D., FACP, discusses Safety Lead-In from the Beacon Study 48% Overall Response Rate
Scott Kopetz, M.D., Ph.D., FACP, explains Less Predictable Alternate BRAF Mutations Not all BRAF mutations are the same.
Scott Kopetz, M.D., Ph.D., FACP, discusses Getting Patients into Clinical Trial Sooner than Later Start with aggressive cytotoxic backbone
Scott Kopetz, M.D., Ph.D., FACP, explains the Rare Clones of KRAS Mutant Cells Able to identify resistant clones
Scott Kopetz, M.D., Ph.D., FACP, explains BRAF V600E Mutation BRAF with EGFR Provided Synergy.